You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Draft cost recovery impact statements (annual review of fees and charges 2009-10)
This consultation opened on 2 April 2009 and closed on 8 April 2009.
The Therapeutic Goods Administration (TGA) is proposing to increase fees and charges for the Prescription Medicine, Non Prescription Medicine, Complementary Medicine and Blood and Tissue Sectors for 2009-10 above the agreed indexation rate. The increases are planned to take effect from 1 July 2009.
The Department of Finance and Deregulation's new cost recovery guidelines require TGA to complete cost recovery impact statements (CRIS) and consult the industry as part of this process.
- Annual review of fees and charges 2009-10 - Blood and Tissues (pdf,111kb)
- Annual review of fees and charges 2009-10 - Complementary Medicines (pdf,89kb)
- Annual review of fees and charges 2009-10 - Non-Prescription (Registered) Medicines (pdf,90kb)
- Annual review of fees and charges 2009-10 - Prescription Medicines (pdf,86kb)